Allogene Therapeutics Inc
ALLO1.175USD
+0.095+8.80%
交易中 （美东）报价延迟15分钟
256.85M总市值
亏损市盈率 TTM
关于 Allogene Therapeutics Inc 公司
Allogene Therapeutics, Inc. 是一家临床阶段的免疫肿瘤学公司。该公司专注于开发用于治疗癌症和自身免疫性疾病的基因工程同种异体 T 细胞候选产品。该公司专注于四个核心项目：大 B 细胞淋巴瘤 (LBCL)、慢性淋巴细胞白血病 (CLL)、自身免疫性疾病和肾细胞癌。该公司正在利用蛋白质工程、基因编辑、基因插入和先进的专有 T 细胞制造技术开发多种同种异体嵌合抗原受体 (CAR) T 细胞候选产品。其候选产品 cemacabtagene ansegedleucel（简称 cema-cel）是一种工程同种异体 CAR T 细胞候选产品，靶向 CD19，CD19 是一种在 B 细胞细胞表面表达的蛋白质，也是 B 细胞驱动的血液系统恶性肿瘤的经过验证的靶标。该公司专注于开发用于 LBCL 和 CLL 的 cema-cel。其产品线还包括 ALLO-316、ALLO-329 和 ALLO-647。
公司简介
公司代码ALLO
公司名称Allogene Therapeutics Inc
上市日期Oct 11, 2018
CEODr. David D Chang, M.D., Ph.D.
员工数量226
证券类型Ordinary Share
年结日Oct 11
公司地址210 East Grand Avenue
城市SOUTH SAN FRANCISCO
上市交易所NASDAQ Global Select Consolidated
国家United States of America
邮编94080
电话16504572700
网址https://allogene.com/
公司代码ALLO
上市日期Oct 11, 2018
CEODr. David D Chang, M.D., Ph.D.
公司高管
名称
名称/职务
职务
持股
持股变动
Dr. Arie S. Belldegrun, M.D.
Dr. Arie S. Belldegrun, M.D.
Executive Chairman of the Board
Executive Chairman of the Board
7.56M
-3.60%
Dr. David D Chang, M.D., Ph.D.
Dr. David D Chang, M.D., Ph.D.
President, Chief Executive Officer, Co-Founder, Director
President, Chief Executive Officer, Co-Founder, Director
5.72M
-7.46%
Mr. Geoffrey M. (Geoff) Parker
Mr. Geoffrey M. (Geoff) Parker
Chief Financial Officer, Executive Vice President
Chief Financial Officer, Executive Vice President
478.17K
-0.90%
Mr. Joshua A. Kazam
Mr. Joshua A. Kazam
Director
Director
303.06K
--
Mr. Owen N. Witte, M.D.
Mr. Owen N. Witte, M.D.
Independent Director
Independent Director
292.83K
+14.59%
Mr. Benjamin Machinas (Ben) Beneski
Mr. Benjamin Machinas (Ben) Beneski
Senior Vice President, Chief Technical Officer
Senior Vice President, Chief Technical Officer
218.51K
--
Mr. Earl Martin Douglas, Esq.
Mr. Earl Martin Douglas, Esq.
Senior Vice President, General Counsel, Compliance Officer and Corporate Secretary
Senior Vice President, General Counsel, Compliance Officer and Corporate Secretary
110.21K
-5.49%
Dr. Zachary Roberts, M.D., Ph.D.
Dr. Zachary Roberts, M.D., Ph.D.
Executive Vice President - Research and Development, Chief Medical Officer
Executive Vice President - Research and Development, Chief Medical Officer
101.90K
-38.68%
Ms. Deborah M. (Debbie) Messemer
Ms. Deborah M. (Debbie) Messemer
Independent Director
Independent Director
45.96K
-44.53%
Mr. Todd B. Sisitsky
Mr. Todd B. Sisitsky
Independent Director
Independent Director
--
--
查看更多
名称
名称/职务
职务
持股
持股变动
Dr. Arie S. Belldegrun, M.D.
Dr. Arie S. Belldegrun, M.D.
Executive Chairman of the Board
Executive Chairman of the Board
7.56M
-3.60%
Dr. David D Chang, M.D., Ph.D.
Dr. David D Chang, M.D., Ph.D.
President, Chief Executive Officer, Co-Founder, Director
President, Chief Executive Officer, Co-Founder, Director
5.72M
-7.46%
Mr. Geoffrey M. (Geoff) Parker
Mr. Geoffrey M. (Geoff) Parker
Chief Financial Officer, Executive Vice President
Chief Financial Officer, Executive Vice President
478.17K
-0.90%
Mr. Joshua A. Kazam
Mr. Joshua A. Kazam
Director
Director
303.06K
--
Mr. Owen N. Witte, M.D.
Mr. Owen N. Witte, M.D.
Independent Director
Independent Director
292.83K
+14.59%
Mr. Benjamin Machinas (Ben) Beneski
Mr. Benjamin Machinas (Ben) Beneski
Senior Vice President, Chief Technical Officer
Senior Vice President, Chief Technical Officer
218.51K
--
收入明细
暂无数据
暂无数据
业务
地区
暂无数据
股东统计
更新时间: 8月3日 周日
更新时间: 8月3日 周日
持股股东
股东类型
持股股东
持股股东
占比
Pfizer Inc
10.07%
TPG Capital, L.P.
8.56%
Citadel Advisors LLC
6.10%
Capital World Investors
5.61%
Lynx1 Capital Advisors LLC
5.06%
Other
64.61%
持股股东
持股股东
占比
Pfizer Inc
10.07%
TPG Capital, L.P.
8.56%
Citadel Advisors LLC
6.10%
Capital World Investors
5.61%
Lynx1 Capital Advisors LLC
5.06%
Other
64.61%
股东类型
持股股东
占比
Investment Advisor
34.01%
Hedge Fund
16.69%
Private Equity
14.32%
Corporation
10.60%
Investment Advisor/Hedge Fund
10.50%
Individual Investor
7.08%
Research Firm
5.09%
Venture Capital
0.83%
Bank and Trust
0.16%
Other
0.72%
机构持股
更新时间: 7月1日 周二
更新时间: 7月1日 周二
报告期
机构数
持股数
持股占比
持股变动
2025Q2
408
225.54M
103.12%
-7.62M
2025Q1
437
219.29M
100.27%
-22.18M
2024Q4
434
209.87M
100.10%
-25.68M
2024Q3
441
205.03M
101.51%
-25.11M
2024Q2
447
205.90M
102.27%
+9.93M
2024Q1
446
170.59M
100.21%
-14.52M
2023Q4
455
160.71M
95.67%
-29.40M
2023Q3
461
177.28M
107.46%
-30.31M
2023Q2
461
179.96M
123.50%
-2.72M
2023Q1
465
163.54M
112.33%
-14.45M
查看更多
股东持股明细
名称
持股数
占比
持股变动
变动比例
公告日期
Pfizer Inc
22.03M
10.07%
--
--
Mar 31, 2025
TPG Capital, L.P.
18.72M
8.56%
--
--
Mar 31, 2025
Citadel Advisors LLC
10.20M
4.66%
+4.85M
+90.75%
Mar 31, 2025
Capital World Investors
12.27M
5.61%
+5.37M
+77.85%
Mar 31, 2025
Lynx1 Capital Advisors LLC
11.06M
5.06%
+182.29K
+1.68%
Mar 31, 2025
BlackRock Institutional Trust Company, N.A.
10.81M
4.94%
-33.81K
-0.31%
Mar 31, 2025
Darwin Global Management Ltd
10.45M
4.78%
+10.45M
--
Mar 31, 2025
The Vanguard Group, Inc.
8.07M
3.69%
+91.07K
+1.14%
Mar 31, 2025
Belldegrun (Arie S)
7.56M
3.46%
-282.53K
-3.60%
Mar 31, 2025
Fidelity Management & Research Company LLC
7.39M
3.38%
-16.37M
-68.89%
Mar 31, 2025
查看更多
持股ETF
更新时间: 8月2日 周六
更新时间: 8月2日 周六
机构名称
占比
WisdomTree BioRevolution Fund
0.78%
Virtus LifeSci Biotech Clinical Trials ETF
0.73%
Invesco NASDAQ Future Gen 200 ETF
0.44%
Global X Genomics & Biotechnology ETF
0.2%
Zacks Small/Mid Cap ETF
0.14%
iShares Health Innovation Active ETF
0.04%
JPMorgan Fundamental Data Science Small Core ETF
0.04%
Invesco Nasdaq Biotechnology ETF
0.03%
ProShares Ultra Nasdaq Biotechnology
0.03%
iShares Biotechnology ETF
0.02%
查看更多
WisdomTree BioRevolution Fund
占比0.78%
Virtus LifeSci Biotech Clinical Trials ETF
占比0.73%
Invesco NASDAQ Future Gen 200 ETF
占比0.44%
Global X Genomics & Biotechnology ETF
占比0.2%
Zacks Small/Mid Cap ETF
占比0.14%
iShares Health Innovation Active ETF
占比0.04%
JPMorgan Fundamental Data Science Small Core ETF
占比0.04%
Invesco Nasdaq Biotechnology ETF
占比0.03%
ProShares Ultra Nasdaq Biotechnology
占比0.03%
iShares Biotechnology ETF
占比0.02%
分红派息
近5年累计派现
0.00
美元
公告日期
分红计划
股权登记日
现金发放日
除权除息日
暂无数据
拆合股
公告日期
类型
比率
暂无数据
公告日期
类型
比率
暂无数据
